Table 1.
Participant characteristics (n = 429)
| Characteristic | |
|---|---|
| Age, median (range) | 41.1 (17.6–90.6) |
| Female, n (%) | 330 (90.7) |
| Country, n (%) | |
| Canada | 164 (38.2) |
| USA | 147 (34.3) |
| Other | 118 (27.5) |
| Highest level of education, n (%) | |
| Secondary school | 56 (15.5) |
| Post-secondary (university, college, technical school) | 305 (84.5) |
| Rheumatic disease typea, n (%) | |
| Rheumatoid arthritis | 247 (57.6) |
| Osteoarthritis | 58 (13.5) |
| Psoriatic arthritis | 45 (10.5) |
| Systemic lupus erythematosus | 43 (10.0) |
| Sjogren syndrome | 32 (7.5) |
| Ankylosing spondylitis | 27 (6.3) |
| Juvenile idiopathic arthritis | 21 (4.9) |
| Mixed connective tissue disease | 19 (4.4) |
| Gout | 9 (2.1) |
| Systemic sclerosis | 4 (0.9) |
| Systemic vasculitis | 4 (0.9) |
| Myositis | 4 (0.9) |
| Other | 33 (7.7) |
| Disease severity (past week)b, n (%) | |
| Under control | 54 (14.8) |
| Mild | 113 (31.0) |
| Moderate | 152 (41.6) |
| Severe | 46 (12.6) |
| Duration of diagnosis, n (%) | |
| Less than 1 year | 58 (13.5) |
| 1 to 5 years | 145 (33.8) |
| 6 to 10 years | 101 (23.5) |
| Over 10 years | 125 (29.1) |
| Medications, n (%)c | |
| Prescription medication(s) | 339 (79.0) |
| csDMARDd | 261 (60.8) |
| Methotrexate | 144 (33.6) |
| Chloroquine | 134 (31.2) |
| Hydroxychloroquine | 129 (30.1) |
| Biologic or targeted DMARD | 170 (39.6) |
| Corticosteroid | 91 (21.2) |
| Non-prescription medication(s) | 137 (31.9) |
| Tested for COVID-19 | |
| No | 310 (91.2) |
| Yes | 30 (8.8) |
| Positive test | 3 (10.0) |
| Negative test | 27 (90.0) |
aNot discrete as participants can report ≥ 1 type
bDisease activity was self-reported
cNot discrete as participants can report ≥ 1 medication
dOnly the most commonly prescribed csDMARDs are listed
Number of missing responses ranged from 0 (0%) to 113 (26.3%)
csDMARD, conventional synthetic disease-modifying anti-rheumatic drug